Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Diagnostic Laboratory, |
RCV000408759 | SCV000484849 | likely pathogenic | Blepharophimosis, ptosis, and epicanthus inversus syndrome | 2016-11-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003678999 | SCV004412262 | likely pathogenic | not provided | 2023-04-24 | criteria provided, single submitter | clinical testing | This missense change has been observed in individual(s) with clinical features of blepharophimosis, ptosis, and epicanthus inversus syndrome (Invitae). It has also been observed to segregate with disease in related individuals. This sequence change replaces methionine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 65 of the FOXL2 protein (p.Met65Ile). This variant is not present in population databases (gnomAD no frequency). ClinVar contains an entry for this variant (Variation ID: 369892). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This variant disrupts the p.Met65 amino acid residue in FOXL2. Other variant(s) that disrupt this residue have been observed in individuals with FOXL2-related conditions (PMID: 18642388; Invitae), which suggests that this may be a clinically significant amino acid residue. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |